Empagliflozin after acute myocardial infarction: Results of the EMPACT-MI Trial

Reported from ACC.24

Mirvat Alasnag interviews Javed Butler about the EMPACT-MI trial which he presented at ACC.24 in Atlanta.

Among patients at increased risk for heart failure after acute MI, treatment with empagliflozin did not lead to a significantly lower risk of first hospitalization for heart failure or death from any cause than placebo.
Despite missing its primary endpoint, SGLT-2 inhibitors show potential in heart failure prevention.